Clinical trials: Depressive; Behavioral Disorder
Major Depressive Disorder, Insomnia
Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon
Hypothesis I: Patients in the SSRI + ramelteon treatment group will achieve remission (defined as an IDS-C30 score of 11 or less) more quickly than those in the SSRI + placebo group.
- Trial name
- TAKEDA (NCT00642694)
- Testing
- Escitalopram, Ramelteon
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder, Post-Traumatic Stress Disorder (PTSD)
PET Imaging of mGLuR5 With Drug Challenge
This study is designed to look at that involvement of a process in the brain called the glutamate system in depression. Participants will undergo a screening session, up to two functional Magnetic Resonance Imaging (fMRI) scans…
- Trial name
- NCT01691092
- Testing
- Ketamine
- Where
- 3 sites in United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Yale University
Perinatal Depression, Postpartum Depression
Development, Feasibility and Acceptability of Fathers and Babies (FAB): A Pilot Study
During this project the investigators will develop and pilot test a companion intervention for fathers (Fathers and Babies-FAB), to supplement the Mothers and Babies Course (MB) that provides stress and mood management tools for…
- Conditions
- Perinatal Depression, Postpartum Depression, Depression
- Trial name
- NCT03427528
- Testing
- Fathers and Babies (FAB), MB 1-on-1 plus TXT
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Major Depressive Disorder
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
An outpatient study to evaluate the safety and efficacy of cariprazine as adjunct to antidepressant therapy (ADT) in participants with major depressive disorder (MDD) who have an inadequate response to ADT alone.
- Trial name
- NCT01469377
- Testing
- Cariprazine
- Where
- 72 sites in United States, Estonia and 4 more
- Volunteers
- 819 people
- Sponsor
- Forest Laboratories
Depression, Anxious Depression
Ketamine for Depression: An MRI Study
Ketamine has been shown to decrease symptoms of anxious depression quickly. This decrease has been shown to last for up to one month.
- Conditions
- Depression, Anxious Depression, Major Depressive Disorder
- Trial name
- NCT02544607
- Testing
- Ketamine, Magnetic Resonance Imaging (MRI)
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Severe Asthma, Moderate or Severe Major Depressive Disorder
Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder
The purpose is to determine if: 1) Escitalopram treatment will be associated with less oral corticosteroid use than placebo in outpatients with severe asthma and moderate or severe major depressive disorder (MDD).
- Trial name
- NCT00621946
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Texas Southwestern Medical Center
Depression, Obesity
Research Aimed at Improving Both Mood and Weight
The RAINBOW study is an NIH R01-funded randomized controlled trial to evaluate the clinical and cost effectiveness and implementation potential of a primary care integrated multicondition intervention program to help improve mood…
- Trial name
- RAINBOW-ENGAGE (NCT02246413)
- Testing
- RAINBOW Intervention Program
- Where
- 2 sites in United States
- Volunteers
- 409 people
- Sponsor
- Palo Alto Medical Foundation
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder.
- Trial name
- NCT00969150
- Testing
- Levomilnacipran ER
- Where
- 25 sites in United States
- Volunteers
- 362 people
- Sponsor
- Forest Laboratories
Treatment Resistant Depression
Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
This study is looking at the safety and efficacy of low field magnetic stimulation (LFMS) for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them.
- Trial name
- RAPID (NCT01654796)
- Testing
- Low Field Magnetic Stimulation (LFMS)
- Where
- 6 sites in United States
- Volunteers
- 84 people
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Major, Postpartum Depression
Mommy-Baby Treatment for Perinatal Depression
Perinatal depression is a major public health problem, affecting 15% of women during pregnancy through the postpartum period, with adverse consequences for the mother, the fetus, the infant, and the family.
- Trial name
- NCT01744041
- Testing
- Dyadic Interpersonal Psychotherapy, Enhanced Treatment as Usual
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Washington University School of Medicine
Acute Coronary Syndrome, Depression
MBCT Delivered Via Group Videoconferencing for ACS Syndrome Patients With Depressive Symptoms
Brief Summary: The aim of this study is to explore the initial feasibility and acceptability of (a) Mindfulness-Based Cognitive Therapy (MBCT) adapted for ACS patients; (b) the group videoconferencing delivery medium; and (c)…
- Conditions
- Acute Coronary Syndrome, Depression, Myocardial Infarction, Unstable Angina
- Trial name
- NCT04231097
- Testing
- MBCT intervention for ACS patients
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Major
Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms
This is a randomised double-blind clinical trial. The aim is to compare the efficacy and mechanisms of action of psilocybin, the primary psychoactive substance in 'magic mushrooms', with the selective serotonin reuptake inhibitor…
- Trial name
- Psilodep-RCT (NCT03429075)
- Testing
- Psilocybin + Escitalopram
- Where
- United Kingdom
- Volunteers
- 59 people
- Sponsor
- Imperial College London
Alcoholism, Depression
Pharmacological Intervention Project (Fluoxetine)
This is a large scale study involving fluoxetine (Prozac) versus a placebo in the treatment of adolescents with alcohol use disorder (AUD) and major depression (MDD).
- Trial name
- FIDAA (NCT00027378)
- Testing
- fluoxetine (Prozac)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
This study is designed to evaluate the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) using the NeoSync EEG Synchronized TMS device (NEST) in subjects with Major Depressive Disorder.
- Trial name
- NEST-MDD (NCT01370733)
- Testing
- NEST-1 (NeoSync EEG Synchronized TMS)
- Where
- 18 sites in United States
- Volunteers
- 202 people
- Sponsor
- Wave Neuroscience
Mild Cognitive Impairment (MCI), Depression
Brain Aging and Treatment Response in Geriatric Depression
The proposed project will evaluate the role of neuroimaging biomarkers of brain aging (i.e., neurodegenerative and vascular brain changes) and mild cognitive impairment in the patterns of treatment response to memantine combined…
- Trial name
- NCT01902004
- Testing
- Escitalopram, Memantine
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- University of California, Los Angeles
Major Depressive Disorder
Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults
This study is designed to evaluate the safety and efficacy of the Fisher Wallace Stimulator FW-200 to deliver Cranial Electrotherapy Stimulation (CES) for the treatment of moderate to severe Major Depressive Disorder (MDD) in…
- Trial name
- CES-MDD (NCT05384041)
- Testing
- Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)
- Where
- United States
- Volunteers
- 255 people
- Sponsor
- Fisher Wallace Laboratories
Major Depressive Disorder
Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine
A 6-cohort single ascending dose (SAD) study will be conducted in healthy volunteers utilizing a slow-infusion intravenous (IV) route of administration.
- Trial name
- NCT04711005
- Testing
- (2R,6R)-Hydroxynorketamine hydrochloride
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Depression
Org 24448 to Treat Major Depression
This study will evaluate the effectiveness of the experimental drug, Org 24448, for short-term treatment of depression. It will examine the effects of the drug on symptoms, such as low mood and persistent sadness, poor sleep and…
- Trial name
- NCT00113022
- Testing
- Org 24448
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Institute of Mental Health (NIMH)
Depression
Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults
This study will evaluate the effectiveness of memantine in improving rehabilitation outcomes and preventing major depressive disorder in older adults who have been admitted to a rehabilitation hospital for a hip fracture or…
- Trial name
- NCT00183729
- Testing
- Memantine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Eric Lenze
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). This study will investigate the safety, efficacy, and tolerability of DVS SR versus escitalopram in women with major…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00406640
- Testing
- Desvenlafaxine succinate sustained-release (DVS SR), Escitalopram
- Where
- 70 sites in United States, Argentina and 4 more
- Volunteers
- 595 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer